<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03387462</url>
  </required_header>
  <id_info>
    <org_study_id>17-22864</org_study_id>
    <secondary_id>1R01MH109320-01</secondary_id>
    <nct_id>NCT03387462</nct_id>
  </id_info>
  <brief_title>DOT Diary Optimization Pilot</brief_title>
  <official_title>DOT Diary Optimization Pilot</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Public Health Foundation Enterprises, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>San Francisco Department of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AiCure</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Public Health Foundation Enterprises, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The researchers are working with a technology company, AiCure, to develop a smartphone app,
      DOT Diary, which combines two drug adherence strategies. DOT Diary reminds people when it is
      time to take their medication, and uses motion-sensing technology to visually and
      automatically confirm the pill was swallowed. The goal of this study is to understand
      people's experiences using this new app while taking HIV pre-exposure prophylaxis (PrEP) for
      the prevention of HIV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the DOT Diary research project, the AiCure aDOT smartphone app has been adapted for use in
      monitoring and supporting HIV pre-exposure prophylaxis (PrEP) use among young men who have
      sex with men (YMSM). The aDOT app uses automated directly observed therapy (DOT) that use the
      smartphone camera and artificial intelligence software to confirm that the right person is
      taking the right medication at the right time. A sexual diary has been integrated into the
      aDOT app to assist YMSM in understanding whether they are receiving protection from PrEP for
      individual sexual episodes, and when it is particularly important to take PrEP (e.g. after a
      sexual episode).

      In the next stage of app development, the researchers are conducting this study to identify
      areas of the app that require refinement to maximize the acceptability and ease of use of the
      DOT adherence monitoring app. The researchers will assess overall acceptability and ease of
      use of the integrated DOT Diary (D2) app over an 8 week period.The goal of this pilot study
      will be to refine and optimize the app for further testing in a larger and longer pilot study
      among YMSM at risk for HIV acquisition. The researchers will conduct this pilot protocol
      among YMSM in Atlanta and San Francisco Bay Area, two metropolitan regions heavily impacted
      by HIV, yet differing in sociodemographics, as well as in the availability and uptake of HIV
      prevention services, including PrEP. These diverse research locations will allow collection
      of data to inform app development among a broad group of YMSM.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 28, 2018</start_date>
  <completion_date type="Actual">August 30, 2018</completion_date>
  <primary_completion_date type="Actual">August 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DOT Diary Mobile App Acceptability</measure>
    <time_frame>8 weeks</time_frame>
    <description>System Usability Scale (SUS) of 1-100 regarding key attributes of acceptability of DOT Diary over 8 weeks by MSM on PrEP, in order to identify potential improvements to the app to maximize acceptability. Higher numbers indicate more favorable responses regarding acceptability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DOT Diary Mobile App Ease of Use</measure>
    <time_frame>8 weeks</time_frame>
    <description>5-point Likert scale (1=strongly disagree that app is easy to use; 5=strongly agree that app is easy to use) of key attributes of ease of use of DOT Diary over 8 weeks by MSM on PrEP.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence and Persistence of Use of the DOT and Sexual Diary Components of DOT Diary by Young MSM on PrEP</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percentage of doses taken with visual confirmation of pill ingestion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Situations and Reasons for Sub-optimal Use of the App</measure>
    <time_frame>8 weeks</time_frame>
    <description>Combined analysis of situations and reasons for sub-optimal use of the app, for the purpose of app optimization</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Adherence, Medication</condition>
  <condition>Risk Behavior</condition>
  <condition>Pre-Exposure Prophylaxis</condition>
  <condition>HIV Prevention</condition>
  <arm_group>
    <arm_group_label>DOT Diary Optimization Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DOT Diary mobile app and Emtricitabine / Tenofovir Disoproxil Oral Tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine / Tenofovir Disoproxil Oral Tablet</intervention_name>
    <description>Open label daily emtricitabine/tenofovir disoproxil oral tablet</description>
    <arm_group_label>DOT Diary Optimization Intervention</arm_group_label>
    <other_name>Truvada</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DOT Diary mobile app</intervention_name>
    <description>DOT Diary mobile application for tracking medication adherence and sexual activities.</description>
    <arm_group_label>DOT Diary Optimization Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Self-identifies as a man

          -  Age 18-35 at enrollment

          -  Reports having anal sex with a man or trans woman in the past 12 months and one or
             more of the following criteria in the past 12 months:

               -  Any condomless anal sex (not in a mutually monogamous relationship with an
                  HIV-negative partner)

               -  Two or more anal sex partners

               -  Self-reported STI (gonorrhea, chlamydia, syphilis)

               -  Having a known HIV-positive sexual partner

          -  HIV-negative as determined by a negative 4th generation HIV test at screening and
             negative rapid 4th generation test at enrollment

          -  Currently taking PrEP or interested in initiating PrEP

          -  Eligible to take PrEP

               -  Creatinine clearance â‰¥60 ml/min as estimated by Cockcroft-Gault equation at
                  screening

               -  Hepatitis B surface antigen (HBsAg) negative

          -  Willing and able to provide written informed consent

          -  Able to read and speak English

          -  Smartphone ownership compatible with DOT Diary

          -  Meets local locator requirements

        Exclusion Criteria:

          -  Any reactive HIV test at screening or enrollment

          -  Signs or symptoms of acute HIV infection at screening or enrollment

          -  History of pathological bone fracture not related to trauma

          -  Taking nephrotoxic medications

          -  History of participation in the active arm of an HIV vaccine trial

          -  In a mutually monogamous sexual relationship with an HIV-negative partner for the past
             12 months

          -  Does not live, work or play in Atlanta Metropolitan Area, San Francisco, Alameda,
             Marin, Contra Costa, Santa Clara, or San Mateo Counties

          -  Unable to commit to study participation for 8 weeks

          -  Any medical, psychiatric, or social condition or other responsibilities that, in the
             judgment of the investigator, would make participation in the study unsafe, complicate
             interpretation of study outcome data, or otherwise interfere with achieving the study
             objectives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Self-identify as a man</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Buchbinder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bridge HIV, San Francisco Department of Public Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bridge HIV, San Francisco Department of Public Health</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University, School of Public Health</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 1, 2017</study_first_submitted>
  <study_first_submitted_qc>December 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2018</study_first_posted>
  <results_first_submitted>February 5, 2020</results_first_submitted>
  <results_first_submitted_qc>February 5, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 19, 2020</results_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Public Health Foundation Enterprises, Inc.</investigator_affiliation>
    <investigator_full_name>Susan Buchbinder</investigator_full_name>
    <investigator_title>Director, Bridge HIV</investigator_title>
  </responsible_party>
  <keyword>Adherence</keyword>
  <keyword>PrEP</keyword>
  <keyword>HIV Prevention</keyword>
  <keyword>Truvada</keyword>
  <keyword>HIV Risk Reduction</keyword>
  <keyword>Mobile App</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT03387462/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT03387462/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited online and via social media, as well as through in-person community outreach.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>DOT Diary Optimization Intervention</title>
          <description>DOT Diary mobile app and Emtricitabine / Tenofovir Disoproxil Oral Tablet
Emtricitabine / Tenofovir Disoproxil Oral Tablet: Open label daily emtricitabine/tenofovir disoproxil oral tablet
DOT Diary mobile app: DOT Diary mobile application for tracking medication adherence and sexual activities.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>4 Weeks</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>8 Weeks</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>18-35 years old, eligible, and willing to take PrEP</population>
      <group_list>
        <group group_id="B1">
          <title>DOT Diary Optimization Intervention</title>
          <description>DOT Diary mobile app and Emtricitabine / Tenofovir Disoproxil Oral Tablet
Emtricitabine / Tenofovir Disoproxil Oral Tablet: Open label daily emtricitabine/tenofovir disoproxil oral tablet
DOT Diary mobile app: DOT Diary mobile application for tracking medication adherence and sexual activities.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.4" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>DOT Diary Mobile App Acceptability</title>
        <description>System Usability Scale (SUS) of 1-100 regarding key attributes of acceptability of DOT Diary over 8 weeks by MSM on PrEP, in order to identify potential improvements to the app to maximize acceptability. Higher numbers indicate more favorable responses regarding acceptability.</description>
        <time_frame>8 weeks</time_frame>
        <population>MSM eligible for or taking PrEP</population>
        <group_list>
          <group group_id="O1">
            <title>DOT Diary Optimization Intervention</title>
            <description>DOT Diary mobile app and Emtricitabine / Tenofovir Disoproxil Oral Tablet
Emtricitabine / Tenofovir Disoproxil Oral Tablet: Open label daily emtricitabine/tenofovir disoproxil oral tablet
DOT Diary mobile app: DOT Diary mobile application for tracking medication adherence and sexual activities.</description>
          </group>
        </group_list>
        <measure>
          <title>DOT Diary Mobile App Acceptability</title>
          <description>System Usability Scale (SUS) of 1-100 regarding key attributes of acceptability of DOT Diary over 8 weeks by MSM on PrEP, in order to identify potential improvements to the app to maximize acceptability. Higher numbers indicate more favorable responses regarding acceptability.</description>
          <population>MSM eligible for or taking PrEP</population>
          <units>Score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.8" spread="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>DOT Diary Mobile App Ease of Use</title>
        <description>5-point Likert scale (1=strongly disagree that app is easy to use; 5=strongly agree that app is easy to use) of key attributes of ease of use of DOT Diary over 8 weeks by MSM on PrEP.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DOT Diary Optimization Intervention</title>
            <description>DOT Diary mobile app and Emtricitabine / Tenofovir Disoproxil Oral Tablet
Emtricitabine / Tenofovir Disoproxil Oral Tablet: Open label daily emtricitabine/tenofovir disoproxil oral tablet
DOT Diary mobile app: DOT Diary mobile application for tracking medication adherence and sexual activities.</description>
          </group>
        </group_list>
        <measure>
          <title>DOT Diary Mobile App Ease of Use</title>
          <description>5-point Likert scale (1=strongly disagree that app is easy to use; 5=strongly agree that app is easy to use) of key attributes of ease of use of DOT Diary over 8 weeks by MSM on PrEP.</description>
          <units>Score on a scale (Likert)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adherence and Persistence of Use of the DOT and Sexual Diary Components of DOT Diary by Young MSM on PrEP</title>
        <description>Percentage of doses taken with visual confirmation of pill ingestion</description>
        <time_frame>8 weeks</time_frame>
        <population>MSM eligible for or taking PrEP</population>
        <group_list>
          <group group_id="O1">
            <title>DOT Diary Optimization Intervention</title>
            <description>DOT Diary mobile app and Emtricitabine / Tenofovir Disoproxil Oral Tablet
Emtricitabine / Tenofovir Disoproxil Oral Tablet: Open label daily emtricitabine/tenofovir disoproxil oral tablet
DOT Diary mobile app: DOT Diary mobile application for tracking medication adherence and sexual activities.</description>
          </group>
        </group_list>
        <measure>
          <title>Adherence and Persistence of Use of the DOT and Sexual Diary Components of DOT Diary by Young MSM on PrEP</title>
          <description>Percentage of doses taken with visual confirmation of pill ingestion</description>
          <population>MSM eligible for or taking PrEP</population>
          <units>Percentage of doses taken</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Situations and Reasons for Sub-optimal Use of the App</title>
        <description>Combined analysis of situations and reasons for sub-optimal use of the app, for the purpose of app optimization</description>
        <time_frame>8 weeks</time_frame>
        <population>MSM eligible for or taking PrEP</population>
        <group_list>
          <group group_id="O1">
            <title>DOT Diary Optimization Intervention</title>
            <description>DOT Diary mobile app and Emtricitabine / Tenofovir Disoproxil Oral Tablet
Emtricitabine / Tenofovir Disoproxil Oral Tablet: Open label daily emtricitabine/tenofovir disoproxil oral tablet
DOT Diary mobile app: DOT Diary mobile application for tracking medication adherence and sexual activities.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Situations and Reasons for Sub-optimal Use of the App</title>
          <description>Combined analysis of situations and reasons for sub-optimal use of the app, for the purpose of app optimization</description>
          <population>MSM eligible for or taking PrEP</population>
          <units>Count of participants for each reason</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Technical problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Away from home</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <desc>As daily oral FTC/TDF for PrEP is a licensed medication, the study focused assessment of AEs on the known toxicity profile of the medication, including creatinine elevations / decreases in creatinine clearance, bone fractures / toxicity, and symptoms associated with a start-up syndrome (e.g. diarrhea, nausea, headache, abdominal gas). A targeted symptom review was performed at each visit using a symptom checklist focused on symptoms associated with FTC/TDF.</desc>
      <group_list>
        <group group_id="E1">
          <title>DOT Diary Optimization Intervention</title>
          <description>DOT Diary mobile app and Emtricitabine / Tenofovir Disoproxil Oral Tablet
Emtricitabine / Tenofovir Disoproxil Oral Tablet: Open label daily emtricitabine/tenofovir disoproxil oral tablet
DOT Diary mobile app: DOT Diary mobile application for tracking medication adherence and sexual activities.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Susan Buchbinder</name_or_title>
      <organization>Bridge HIV, San Francisco Department of Public Health</organization>
      <phone>628-217-7479</phone>
      <email>susan.buchbinder@sfdph.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

